
Life Sciences Knowledge
This is the reference layer behind every Vegalab Life Sciences program: what each compound is, how it behaves in the body, what regulators allow, and which delivery claims survive scrutiny. Each page states an evidence tier and a regulatory status so partners can make decisions on facts.
Compound Library
Thirty-seven profiles, from NAD+ precursors and antioxidants to incretin drugs and research peptides. Each profile gives molecular weight, solubility, half-life, degradation route, current route of administration, regulatory status by market, WADA status where relevant, and the evidence tier (in vitro, animal, human trial, approved). The library describes compounds; it does not offer them. Start with NMN, NAD+, glutathione or semaglutide for the most complete entries. Profiles also link to the Health Areas and Delivery Challenges where each compound appears.
Technology and What Doesn't Work
The Technology section explains multi-layer nano-encapsulation, compares it with liposomes, lipid nanoparticles and polymer shells, reviews the state of oral peptide delivery, and describes how bioavailability is measured. The What Doesn't Work section examines popular delivery claims (oral glutathione pills, oral NAD+ capsules, products labeled liposomal) against the published evidence, including where our own platform faces the same limits. Technology pages give the measurement methods behind every delivery statement on this site, so partners can check how a result was obtained.
Regulatory and Stewardship
Where a compound sits (supplement, natural health product, cosmetic ingredient, investigational drug, approved drug or unapproved research compound) determines what can be made and said. This section covers the supplement versus drug boundary, the status of peptides by market, anti-doping rules for sport, and the list of products Vegalab will not make. Pages are reviewed against current regulator guidance and the annual WADA list, and each carries the date basis of its status statements.
Key facts
- Dietary supplements in the US may not claim to diagnose, treat, cure or prevent disease (21 U.S.C. 343(r)(6), DSHEA 1994)
- The WADA Prohibited List is updated annually and applies to all athletes under the World Anti-Doping Code (WADA Prohibited List 2026)
- Canada regulates natural health products under a distinct licensing framework requiring a product license (Natural Health Products Regulations, SOR/2003-196)
How our delivery technology applies
Every Knowledge page ends in the same question: what does encapsulation change for this molecule? For some the answer is stability on shelf, for others dispersion of a poorly soluble compound, protection from proteases, residence at a mucosal surface, or release rate. For some the honest answer is that delivery is not the limiting factor. The Knowledge section records both.
Have a compound we have not profiled? Ask for a feasibility review.
Related reading
Last updated:

